Cancer Immunotherapy Market – Global Industry Trends and Forecast 2022 to 2030

The global cancer immunotherapy market size is expected to be worth around US$ 130.6 billion by 2030, according to a new report by Vision Research Reports.

The global cancer immunotherapy market size was valued at US$ 60.1 billion in 2020 and is anticipated to grow at a CAGR of 10.6% during forecast period 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38822

Report Coverage

Report Scope Details
Market Size US$ 130.6 Bn by 2030
Growth Rate CAGR of 10.6% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Product, cancer type
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned F. Hoffmann-La Roche, Ltd; AstraZeneca; Bristol-Myers Squibb Company; Pfizer, Inc.; Merck & Co., Inc.; Novartis AG.

Growth Factors

Growing adoption of advanced cancer therapeutic options coupled with rising cancer incidence has been one of the primary growth stimulants for the market. Healthcare providers are focusing on improving cancer therapeutic facilities and a reduction in the recurrence rate of tumor post chemotherapy.

Rising R&D activities in the cancer immunotherapy field is resulting in the introduction of advanced variants with enhanced efficacy and effectiveness of treatment. Immuno-oncology have shown promising results with improved survival and lower toxicity. A paradigm shift from traditional chemotherapies to immunotherapies is propelling the overall market.

By Product Analysis

Monoclonal antibodies (mAbs) were the most prominent product segment in 2018. Increasing investments in R&D of monoclonal antibodies as naked antigen binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have opened new avenues of revenue generation for companies that provide oncology therapeutics.

Immunomodulators, unlike other chemo-immunotherapy drugs, are used to modulate immune system of patients, which in turn, enhance the activity of immune system against tumors.

By Cancer Type Analysis

By type, the global cancer immunotherapy market has been segmented into lung, breast, colorectal, melanoma, prostate, head & neck, ovarian, and pancreatic cancer. Majority of immunotherapy drugs including few monoclonal antibodies and checkpoint inhibitors are approved for treatment of NSCLC.

Checkpoint inhibitors are used as a first-line treatment in patients suffering from advanced lung tumor. Opdivo, Keytruda, and Tecentriq are immunotherapeutic drugs approved for lung tumor.

Cancer immunotherapies are being increasingly used for melanoma therapeutics. The growth of the melanoma segment can be attributed to development of new products, large number of FDA approvals, and extensive R&D in this field.

By Regional Analysis

North America held the largest revenue share in 2018. Rising incidence of the disease, increasing ease of access to modern therapeutics, coupled with expanding geriatric population, are contributing to the growth of the regional market.

Asia Pacific is expected to experience the fastest growth during the forecast period. New and advanced immunotherapy drugs are being introduced in China and Japan. These countries have several ongoing clinical trials as well as FDA approvals for new drug molecules and combination therapies.

Key Players

 Amgen Inc.; AstraZeneca; F. Hoffman La Roche; Bayer AG; Bristol-Myers Squibb; Eli Lilly and Co.; Merck and Co.; Novartis; and Pfizer.

Market Segmentation

  • By Product
    • Monoclonal Antibodies
    • Immunomodulators
    • Oncolytic Viral Therapies and Cancer Vaccines
  • By Cancer Type
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Melanoma
    • Prostate Cancer
    • Head and Neck Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
  • Regional
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • India
      • China
      • Japan
      • South Korea
      • Australia
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • U.A.E.

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38822

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Cancer Immunotherapy Market, By Product

7.1.  Cancer Immunotherapy Market, by Product, 2021-2030

7.1.1.    Monoclonal Antibodies

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Immunomodulators

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Oncolytic Viral Therapies and Cancer Vaccines

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Cancer Immunotherapy Market, By Cancer Type

8.1.  Cancer Immunotherapy Market, by Cancer Type, 2021-2030

8.1.1.    Lung Cancer

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Breast Cancer

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Colorectal Cancer

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Melanoma

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Prostate Cancer

8.1.5.1.        Market Revenue and Forecast (2017-2030)

8.1.6.    Head and Neck Cancer

8.1.6.1.        Market Revenue and Forecast (2017-2030)

8.1.7.    Ovarian Cancer

8.1.7.1.        Market Revenue and Forecast (2017-2030)

8.1.8.    Pancreatic Cancer

8.1.8.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Cancer Immunotherapy Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Product (2017-2030)

9.1.2.    Market Revenue and Forecast, by Cancer Type (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Product (2017-2030)

9.2.2.    Market Revenue and Forecast, by Cancer Type (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Product (2017-2030)

9.3.2.    Market Revenue and Forecast, by Cancer Type (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Product (2017-2030)

9.4.2.    Market Revenue and Forecast, by Cancer Type (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Product (2017-2030)

9.5.2.    Market Revenue and Forecast, by Cancer Type (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by Cancer Type (2017-2030)

Chapter 10.  Company Profiles

10.1.              Amgen Inc.

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              AstraZeneca

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              F. Hoffman La Roche

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Bayer AG

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Bristol-Myers Squibb

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Eli Lilly and Co.; Merck

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Novartis

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Pfizer

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

12.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38822

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com